Papers/PMID:19033020
Selenium supplementation improves antioxidant capacity in vitro and in vivo in patients with coronary artery disease The SElenium Therapy in Coronary Artery disease Patients (SETCAP) Study.
American heart journal2008The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
selenium atom — activates GPX1
Evidence strength: insufficient.Finding“Sodium selenite treatment increased GPx-1 protein expression dose-dependently, achieving a 2.4-fold maximal increase at 289 nmol/L in HCAEC; this increase was associated with a 1.9-fold increase in GPx-1 activity (203 ± 9.2 vs 109 ± 6.2 mmol min−1 mg−1, P <.0001).”
Quoted verbatim from Selenium supplementation improves antioxidant capacity in vitro and in vivo in patients with coronary artery disease The SElenium Therapy in Coronary Artery disease Patients (SETCAP) Study.. - Study
- in vitro · not in humans
- Duration
- 4 days
- Dose
- sodium selenite 5.78 to 578 nmol/L, maximal effect at 289 nmol/L
- Population
- human coronary artery endothelial cells incubated with sodium selenite for 4 days
Selenium supplementation improves antioxidant capacity in vitro and in vivo in patients with coronary artery disease The SElenium Therapy in Coronary Artery disease Patients (SETCAP) Study.2008PMID:1903302010.1016/j.ahj.2008.09.004Industry fundedPermalink